Drugs / CD70.CAR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07297160 | Jun 2026 → Dec 2029 expected | kidney cancer, plasma cell myeloma, sarcoma | Baylor College of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD70.CAR | “CD70.CAR: Three dose levels, and a possible dose level -1 in case of unexpected toxicity at dose level 1, will be evaluated for patients with lymphoma and solid tumors.” NCT07297160 ↗ |
| Known as | CD70 "CAR" T cells | “These CD70 "CAR" T cells are investigational products not approved by the Food and Drug Administration.” NCT07297160 ↗ |
| Action | Deplete | “The doctors then made another change to cause these T cells to kill any cell that has CD70.” NCT07297160 ↗ |
| Modality | Cell therapy | “When binder is joined to a T cell in this way it is called a chimeric receptor or "CAR T cell".” NCT07297160 ↗ |
| Route | Intravenous | “The patient will be given an injection of cells into the vein through an IV at the assigned dose.” NCT07297160 ↗ |